Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index; 35 of the 66 sources its claims cite were checked for support.

A 2025 update on treatment strategies for the Alzheimer’s disease spectrum

Open access
Wu, Chuang-Kuo, Fuh, Jong-Ling · 2025 · Journal of the Chinese Medical Association

Abstract

This review summarizes the 2025 treatment paradigm, including symptomatic agents and anti-amyloid monoclonal antibodies such as lecanemab and donanemab.

Overview

CoChat Summary

## TL;DR

This 2025 review summarizes how Alzheimer’s disease treatment has shifted from symptomatic therapy to biomarker-guided, stage-specific care across the Alzheimer’s disease continuum. It argues that anti-amyloid immunotherapies have changed early-stage management, but benefits are modest and access, safety, and long-term data remain major issues.

## Key findings

  • The paper states that FDA-approved drugs now exist for AD stages 3 to 6, while stages 1 and 2 remain under development.
  • In preclinical/asymptomatic AD, the A4 trial of solanezumab ran for 5 years and found no significant cognitive benefit; about 30% of participants in either arm progressed to symptomatic AD (stage 3 or 4).
  • For stage 3 (MCI due to AD), long trials of cholinesterase inhibitors and memantine lasting 12 to 48 months “consistently failed” to show significant benefit, and the AAN does not recommend ChEIs for MCI.
  • Anti-amyloid immunotherapies changed early-stage care: lecanemab and donanemab were FDA-approved for “early-stage” AD, and the paper says their clinical effect is modest, delaying cognitive decline by about 6 to 12 months.

## Methods

  • This is a narrative review, not an original study; it synthesizes published clinical trials, systematic reviews, guidelines, and real-world evidence on AD treatment.
  • It organizes evidence by the six-stage Alzheimer’s disease continuum, from asymptomatic biomarker-positive disease to severe dementia, and also covers behavioral/psychiatric symptoms, atypical variants, and mixed dementia.
  • The paper draws on named studies and trial data such as A4, lecanemab, donanemab, and other cited trials, but it does not present a new analytic dataset.

## Limitations

  • The paper explicitly notes that early-stage anti-amyloid therapies have only modest clinical benefits and that long-term safety and cost-effectiveness remain to be determined.
  • It states that access to amyloid PET, CSF biomarkers, infusion therapy, and intensive MRI monitoring limits real-world implementation, especially in low-resource settings.
  • Evident from the text: this is a review article, so it depends on previously published studies rather than new primary data or a systematic search protocol; the paper does not state such a protocol.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1097/jcma.0000000000001252

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical abstract
Graphical abstract CC BY-NC-ND · PubMed Central
Fig. 1 Effect of different treatment strategies on cognitive decline over time. This figure illustrates changes in CDR scores over a 15-y follow-up period among individuals with different treatment strategies for Alzheimer’s disease. The y-axis stands for the change in CDR from baseline, with higher values showing greater cognitive decline. The x-axis stands for the years of follow-up assessment. CDR = clinical dementia rating; ChEI= cholinesterase inhibitors.
Fig. 1 Effect of different treatment strategies on cognitive decline over time. This figure illustrates changes in CDR scores over a 15-y follow-up period among individuals with different treatment strategies for Alzheimer’s disease. The y-axis stands for the change in CDR from baseline, with higher values showing greater cognitive decline. The x-axis stands for the years of follow-up assessment. CDR = clinical dementia rating; ChEI= cholinesterase inhibitors.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

23 Valid · 15 Not valid · 14 Not checked · 20 Own results and interpretations

31 more claims · 12 with their cited sources checked

Create a free account to see all 72 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 30
  • Probably not a substantial claim. 12
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 59 references

Cited by

See all 77

Metadata

Authors
Wu, C.-K., & Fuh, J.-L.
Affiliations
  • Brown University (US)
  • National Yang Ming Chiao Tung University (TW)
Corresponding author
Fuh, Jong-Ling
Venue
Journal of the Chinese Medical Association
Published
2025-05-30
Volume
88
Issue
7
Pages
495-502
ISSN
1726-4901 (ISSN-L)
OpenAlex
W4410907062
Cited by
77
References
59
Citations by year
2026: 67 · 2025: 10
FWCI
9.98
Type
journal article
Language
en
Open access
Locations
  • Journal of the Chinese Medical Association (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, anti-amyloid immunotherapy, lecanemab, donanemab, cholinesterase inhibitors, memantine, tau-targeted therapy, neuroinflammation, biomarkers, early diagnosis, dementia treatment, cognitive training, caregiver support, personalized treatment
MeSH terms
Cognitive Training, Alzheimer Disease, Cholinesterase Inhibitors, Dementia, Humans, Memantine, Dopamine Agents, Caregivers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 2025 update on treatment strategies for the Alzheimer’s disease spectrum. https://app.cochat.ai/papers/10.1097/jcma.0000000000001252
The paper
Wu, C.-K., & Fuh, J.-L. (2025). A 2025 update on treatment strategies for the Alzheimer’s disease spectrum. Journal of the Chinese Medical Association. https://doi.org/10.1097/jcma.0000000000001252

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.